Atara Biotherapeutics, Inc. (ATRA)
| Market Cap | 1.54B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -303.81M |
| Shares Out | 81.18M |
| EPS (ttm) | -4.53 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $18.61 |
| Previous Close | $18.61 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 18.83 |
| Day's Range | 18.34 - 19.19 |
| Day's Volume | 930,574 |
| 52-Week Range | 5.69 - 26.23 |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA; the “Company”), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform t...
A Relative Strength Rating upgrade for Atara Biotherapeutics shows improving technical performance. The post Atara Biotherapeutics Clears Technical Benchmark, Hitting 80-Plus RS Rating appeare...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T- cell platform to develop tra...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA; the “Company”), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform t...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T- cell platform to develop tran...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop trans...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop tran...
WHIPPANY, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Bayer and Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced an exclusive worldwide license agreement and research, devel...
Allogeneic cell therapies have a significant cost, convenience and efficiency advantage over autologous. Data from three of the leaders: Allogene, Atara and CRISPR are expected in the next 12-...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop tran...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop tran...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop tran...
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q3 2020 Results - Earnings Call Transcript
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop tran...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop tran...
Atara Biotherapeutics sees its Relative Strength Rating reach the elite 90-plus level.
24/7 Wall St. reviews dozens of analyst research reports each day of the week, and most of the so-called Buy and Outperform ratings come with upside of 8% to 10% for Dow Jones industrials, S&P...
Week 38 MDA Breakout Forecast: Short-Term Picks To Give You An Edge
Atara (ATRA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc.
When it comes to life-threatening illnesses, mesothelioma would rank close to the top of the list.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q2 2020 Results - Earnings Call Transcript
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc.
Atara Biotherapeutics (ATRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Atara Biotherapeutics to Announce Second Quarter 2020 Financial Results on Wednesday, August 5, 2020
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc.
Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
As of late, it has definitely been a great time to be an investor of Atara Biotherapeutics
These companies offer promising pipelines that could deliver in the long term.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transf...
Atara Biotherapeutics (ATRA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Atara Biotherapeutics Inc. (NASDAQ: ATRA) is finding itself caught between a rock and a hard place after Friday’s drug study news.
Bull market or bear market, one fact remains unwavering: Biotech stocks represent the ultimate risk/reward plays.
Atara Biotherapeutics (ATRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Atara Biotherapeutics (ATRA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Atara Biotherapeutics Inc (ATRA) CEO Pascal Touchon on Q1 2020 Results - Earnings Call Transcript
RBC Capital has peered into its crystal ball to reveal some of the market's most exciting biotech stocks. Here are seven that stand out.
Atara Biotherapeutics: Still Bullish On Long-Term Prospects
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q4 2019 Results - Earnings Call Transcript
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel t...
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading, off-the-shelf, allogeneic T-cell immunotherapy company developing novel ...
These two cancer stocks are trading at a pittance compared to their long-term value propositions.
Trade deal optimism coupled with the Santa Claus rally have turned the market super bullish for the last five trading days left this year.
Here we discuss some biotech stocks, which are down this year so far but have the potential to bounce back next year.
Turnaround In Progress: Key Takeaways From Atara Biotherapeutics' Q3 Earnings Call
Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Atara Biotherapeutics' (ATRA) CEO Pascal Touchon on Q3 2019 Results - Earnings Call Transcript
About ATRA
Atara Biotherapeutics, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies f... [Read more...]
| Industry Biotechnology | IPO Date Oct 16, 2014 |
| CEO Pascal Touchon | Employees 429 |
| Stock Exchange NASDAQ | Ticker Symbol ATRA |
Analyst Forecasts
According to 12 analysts, the average rating for ATRA stock is "Buy." The 12-month stock price forecast is 32.89, which is an increase of 76.73% from the latest price.